semaglutide injections flatiron district The Vitamin Bar Semaglutide Flex-Dose 4 mL Injectable

Note: These rates are from Phase 2 trials with ~300 participants

Data & Comments Data Views Downloads Citations Comments 2 Comments Comments must be written in English

Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis

SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]